Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis Fran SupekMarijeta KraljBiserka Žinić Preclinical Studies 27 September 2007 Pages: 97 - 110
NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2 Miguel MuñozMarisa RossoFrancisco Esteban Preclinical Studies 29 September 2007 Pages: 111 - 118
Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat Qi-Biao SuFan HeShu-Feng Zhou PRECLINICAL STUDIES 06 October 2007 Pages: 119 - 137
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia Markus JensenAndreas EngertAnders Österborg PHASE I STUDIES 20 December 2007 Pages: 139 - 149
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium Thomas E. HutsonSvetislava VukeljaWilliam Berry PHASE I STUDIES 31 January 2008 Pages: 151 - 158
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors Patricia M. LoRussoShirish M. GadgeelCatherine Wheeler PHASE I STUDIES 25 January 2008 Pages: 159 - 167
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells Brigette MaBoon Cher GohTony Mok Phase II Studies 12 September 2007 Pages: 169 - 173
The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas Paolo Andrea ZucaliAlexia BertuzziArmando Santoro PHASE II STUDIES 25 September 2007 Pages: 175 - 181
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer Athanassios ArgirisSanjiv S. AgarwalaSally E. Carty PHASE II STUDIES 02 October 2007 Pages: 183 - 188
Topical henna for capecitabine induced hand–foot syndrome Idris YucelGonullu Guzin Preclinical Studies 21 September 2007 Pages: 189 - 192
A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798) J. J. KnoxX. E. ChenM. Moore SHORT REPORT 04 December 2007 Pages: 193 - 194
